BridgeMD
New treatment option for Adenomyosis
Official title Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients
ClinicalTrials.gov ID: NCT06239376
What this study is testing
- What it's testing
- This randomized clinical trial aims to assess the comparative effectiveness of two distinct endometrial preparation protocols for frozen embryo transfer (FET) among women with adenomyosis undergoing IVF/ICSI. Specifically, it seeks to address the following key questions: 1.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 42, women only
You may be able to join if
- Confirm diagnosis with adenomyosis by using transvaginal ultrasonography (MUSA consensus) and/or pelvic magnetic resonance imaging.
- Age between 18 - 42
- Undergo less or equal to three previous IVF cycles
- Indicate for frozen embryo transfer
- Agree to have not more than two day-3 embryo or one blastocyst (day-5 and day-6) transferred
You likely can't join if
- Embryos from IVM cycle
- Having uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus; unremoved hydrosalpinx, endometrial...
- Having contraindications for exogenous hormones administration: breast cancer, risks of venous thromboembolism
- Embryos from the oocyte donation cycle.
- Patients with a history of GnRH injection within three months, measured from the last GnRHa injection to the study screening date.
See the full eligibility criteria
- Confirm diagnosis with adenomyosis by using transvaginal ultrasonography (MUSA consensus) and/or pelvic magnetic resonance imaging.
- Age between 18 - 42
- Undergo less or equal to three previous IVF cycles
- Indicate for frozen embryo transfer
- Agree to have not more than two day-3 embryo or one blastocyst (day-5 and day-6) transferred
- Not participating in any other study
- Embryos from IVM cycle
- Having uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal leiomyoma, or leiomyoma with endometrial cavity...
- Having contraindications for exogenous hormones administration: breast cancer, risks of venous thromboembolism
- Embryos from the oocyte donation cycle.
- Patients with a history of GnRH injection within three months, measured from the last GnRHa injection to the study screening date.
The study team makes the final eligibility decision.
Where it's taking place
- Ho Chi Minh City, Ho Chi Minh City, Vietnam
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 42 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ho Chi Minh City, Ho Chi Minh City, Vietnam. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.